{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T03:39:08Z","timestamp":1775705948186,"version":"3.50.1"},"reference-count":19,"publisher":"S. Karger AG","issue":"5","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Res Treat"],"published-print":{"date-parts":[[2020]]},"abstract":"<b><i>Background:<\/i><\/b> The aim of this retrospective analysis is to understand the natural history of myxofibrosarcoma (MFS), in particular whether the prognosis can be influenced by histologic grade. <b><i>Methods:<\/i><\/b> We reviewed 229 adult patients with primary MFS of the limbs. We analyzed disease-specific survival (overall survival [OS]) and local recurrence (LR). <b><i>Results:<\/i><\/b> Median age was 70 years (range, 19\u201392). Sixteen (7.0%) were grade 1, 38 (16.6%) grade 2, and 175 (76.4%) grade 3. A worse OS was found in grade 3 MFS (73.1%) than in grade 2 and 1 MFS (91.9 and 100%, respectively) at 5 years (<i>p<\/i> = 0.031). Locally recurred MFS had a worse OS (<i>p<\/i> = 0.018). A better LR-free rate (100% at 5 years) was observed in grade 1 MFS; however, a similar rate was observed between grade 2 and 3 tumors (77.1 and 80.0% at 5 years, respectively, <i>p<\/i> = 0.412). <b><i>Conclusions:<\/i><\/b> Grade 3 MFS has the worst prognosis. Grade 1 MFS have the lowest risk of LR. These data could help identify a high-risk patient group, thus selecting a more careful follow-up for higher-risk patients. Since MFS mostly affects the elderly population, it might be useful to reserve adjuvant treatments (radiotherapy and chemotherapy) to higher-risk patients.<\/jats:p>","DOI":"10.1159\/000506844","type":"journal-article","created":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T21:00:33Z","timestamp":1586379633000},"page":"189-195","source":"Crossref","is-referenced-by-count":31,"title":["Grading in Myxofibrosarcoma of the Extremities Can Predict Survival and Local Control"],"prefix":"10.1159","volume":"43","author":[{"given":"Andrea","family":"Sambri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianmarco","family":"Tuzzato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Spinnato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimiliano","family":"De\u00a0Paolis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide\u00a0Maria","family":"Donati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2020,4,8]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800550"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0b013e3181cf87fa"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-199604000-00001"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197704)39:4<1672::AID-CNCR2820390442>3.0.CO;2-C"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00256-008-0542-4"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.05.1130"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.13161"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/00000372-200308000-00001"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S0344-0338(11)80700-4"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-198209000-00009"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2016.05.015"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-010-1341-4"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000000869"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1985.3.10.1344"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1097\/PAT.0000000000000050"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910330108"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1097\/00003086-198011000-00013"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/jso.24955"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/8517371"}],"container-title":["Oncology Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/506844","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/506844","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T15:54:45Z","timestamp":1745423685000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000506844"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":19,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,5,5]]},"published-print":{"date-parts":[[2020,5,19]]}},"URL":"https:\/\/doi.org\/10.1159\/000506844","archive":["Portico"],"relation":{},"ISSN":["2296-5270","2296-5262"],"issn-type":[{"value":"2296-5270","type":"print"},{"value":"2296-5262","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020]]}}}